Vas Narasimhan, Novartis CEO (Simon Dawson/Bloomberg via Getty Images)
April 27, 2021 10:29 AM EDT
Bioregnum

Now reimag­in­ing home, of­fice sched­ules: No­var­tis CEO Vas Narasimhan sees a new nor­mal in the post-Covid era

It’s not just small biotechs that are look­ing to com­plete­ly reeval­u­ate their need for of­fice space in a post-Covid world. It turns out No­var­tis CEO …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

A service from the Financial Times